PITPNM3 has been proven to be a functional CCL18 receptor in breast tumor cells [29] and T lymphocytes [40], while CCR6 and CCR8 have been proven to be expressed in T lymphocytes [39, 41]. Here, PITPNM3 is linked to breast neoplasm.